June 15, 2018
The North Korean summit is over. Now for the hard part.
President Trump's meeting with Kim Jong-un in Singapore was heavy on drama but ultimately light on specifics. Kim agreed to complete denuclearization, and the U.S. to provide benefits, but all without articulated steps or timetables.
What's next: For all the to-ing and fro-ing ahead of the summit, it may well turn out that the Trump-Kim meeting was the easy part. Now Secretary of State Mike Pompeo and his North Korean counterpart must negotiate an actual plan that leads to complete denuclearization.
The work ahead will be hard and perhaps impossible. Pompeo's first task will be to demonstrate that there indeed is a shared understanding of what the two sides mean by "complete denuclearization," and to elicit a weapons declaration and lock in a timetable for their destruction. The administration should test the possibility that Kim is sincere about disarming without giving away tangible benefits ahead of true demonstrations of commitment. On that count, Trump's pledge to suspend joint military exercises with South Korea was a step in the wrong direction.
Read the Full Article at Axios
More from CNAS
-
Podcast
Defense / Indo-Pacific Security
Hellscape Taiwan: Drones, Deterrence, and the Future of Asymmetric DefenseStacie Pettyjohn joined the Irregular Warfare Podcast to examine how Taiwan could deter—or potentially defeat—a Chinese invasion by transforming the Taiwan Strait into an “unm...
By Stacie Pettyjohn
-
Video
Indo-Pacific Security / Energy, Economics & Security
Analysts Break Down Trump-Xi Meeting and Calls for Stability and CooperationFor perspective on President Trump's trip and the broader U.S.-China relationship, Geoff Bennett spoke with Myron Brilliant and Liza Tobin. Brilliant is at the DGA Group and i...
By Liza Tobin
-
Video
Indo-Pacific Security / Energy, Economics & Security
Rajdeep Sardesai Asks Big Question on US-ChinaThe debate on the Big Question, with Daniel Silverberg, adjunct senior fellow at the Center for a New American Security, explores whether Beijing holds the key to resolving th...
By Daniel Silverberg
-
China’s Pharmaceutical Weapon
Commentary
Until SAPIR is extended to biologically derived drugs, until the FDA clears the bovine pathway, and until at least one American-owned heparin manufacturer operates on US soil,...
By Jennifer Hendrixson White
